Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Price Target at $10.81

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $10.81.

A number of research firms recently weighed in on OPRX. B. Riley reiterated a “buy” rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Stifel Nicolaus raised their price objective on OptimizeRx from $12.50 to $16.00 and gave the stock a “buy” rating in a research report on Monday, June 9th. JMP Securities raised their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a “market outperform” rating in a research report on Tuesday, May 13th. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Wall Street Zen raised OptimizeRx from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd.

OptimizeRx Trading Up 3.3%

NASDAQ:OPRX opened at $13.55 on Friday. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.25. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $15.71. The firm has a market capitalization of $250.68 million, a price-to-earnings ratio of -16.13, a price-to-earnings-growth ratio of 4.37 and a beta of 1.34. The stock has a fifty day simple moving average of $12.09 and a 200 day simple moving average of $8.35.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. The business had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. Sell-side analysts forecast that OptimizeRx will post -0.33 earnings per share for the current year.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. increased its stake in shares of OptimizeRx by 9.6% during the first quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock worth $137,000 after purchasing an additional 1,387 shares during the period. Bank of New York Mellon Corp increased its stake in shares of OptimizeRx by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company’s stock worth $775,000 after purchasing an additional 1,826 shares during the period. Rhumbline Advisers increased its stake in shares of OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock worth $241,000 after purchasing an additional 2,636 shares during the period. Wells Fargo & Company MN increased its stake in shares of OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after purchasing an additional 2,797 shares during the period. Finally, Barclays PLC increased its stake in shares of OptimizeRx by 13.5% during the fourth quarter. Barclays PLC now owns 30,574 shares of the company’s stock worth $148,000 after purchasing an additional 3,640 shares during the period. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.